Table 1.

Patient, tumor, and treatment characteristics.

	Period I (26 patients, 30 procedures)	Period II (26 patients, 26 procedures)	P value
Age (years, median (range))	69 (34–82)	70 (40–85)	ns
Gender, n (%)
Male	15 (57.7 %)	12 (46.2 %)	ns
Female	11	14
Site of primary tumor (n)
Colon	15	16	ns
Rectum	11	10
Number of mucinous primary tumors	0	3	ns
Tumor grade of primary tumor
High	4	9	ns
Medium	22	14
Low	0	3
Synchronous metastases	13	20	ns
Metachronous metastases	13	6
Indication for RFA
Patient: Advanced age/co-morbidity	8	5	ns
Tumor: Inadequate residual functioning liver parenchyma	18	21
Number of ablated lesions	39*	31	ns
Tumor size of ablated lesion (cm, median (range))	1.5 (1.0–3.2)	1.4 (0.5–4.5)	ns
RFA approach
Percutaneous	7	9	ns
Open surgical	23	17
Time from primary resection to RFA (months, median (range))	17 (2–80)	9 (2–76)	ns
Prior liver resection	6	12	ns
Concomitant liver resection	15	15	ns
Bilobar disease	16	14	ns
Number of lesions (ablated and resected lesions), median	2	2	ns
Size of largest lesion (cm, ablated or resected lesions), median	2.95	2.20	ns
CEA (ng/mL, median (range))	9.9 (1.7–3414)	7.7 (0.5–145)	ns
ASA III	6	9	ns
Median follow-up (months (range))	34 (1–137)	33 (2–78)	ns
Neoadjuvant chemotherapy	6	13	ns
Number of lines of chemotherapy before RFA, median (range)	13 (4–22)	4 (4–12)
Adjuvant chemotherapy	4	13	P = 0.017

^*Including three reablations.